Btk
Bruton tyrosine kinase
Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.
Btk plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. Btk is a kinase expressed exclusively in B cells and myeloid cells and has a well characterized, vital role in B cells highlighted by the human primary immune deficiency disease, X-linked agammaglobulinemia (XLA), which results from mutation in the Btk gene. Btk plays an essential role in the BCR signaling pathway. Antigen binding to the BCR results in B cell receptor oligomerization, Syk and Lyn kinase activation, followed by Btk kinase activation. Once activated, Btk forms a signaling complex with proteins such as BLNK, Lyn, and Syk and phosphorylates phospholipase C (PLC)γ2. This leads to downstream release of intracellular Ca2+ stores and propagation of the BCR signaling pathway through extracellular signal-regulated kinase and NF-κB signaling, ultimately resulting in transcriptional changes to foster B cell survival, proliferation, and/or differentiation.
All Product Categories
-
Btk Related Products (273)
Related Products (273)
-
Recombinant Proteins (19)
-
Antibodies (3)
-
BTK-IN-6
0 ImagesCat. No.: HY-142932BTK-IN-6 is a potent inhibitor of Bruton's Tyrosine Kinase (BTK). BTK is a member of the Tec family of tyrosine kinases and plays an important role in the regulation of early B-cell development and mature B-cell activation and survival. BTK-IN-6 has the potential for the research of immune disorders, cancer, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders, and neurological disorders (extracted from patent WO2021136219A1, compound 8).
-
Faldoritinib
0 ImagesCat. No.: HY-187867CAS No.: 2910764-59-7Faldoritinib is a Tyrosine kinase inhibitor and antineoplastic agent.
-
BTK inhibitor 20
0 ImagesCat. No.: HY-143730CAS No.: 2696450-27-6
-
JAK3/BTK-IN-6
0 ImagesCat. No.: HY-147754CAS No.: 2243136-03-8
-
JAK3/BTK-IN-4
0 ImagesCat. No.: HY-143719CAS No.: 2673196-38-6JAK3/BTK-IN-4 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-4 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 003)
-
ABBV-992
0 ImagesCat. No.: HY-163827CAS No.: 2792171-84-5
-
Pirtobrutinib-13C,d3
0 ImagesCat. No.: HY-131328SSynonyms: LOXO-305-13C,d3Pirtobrutinib-13C,d3 (LOXO-305-13C,d3) is the deuterated, 13C-labeled Pirtobrutinib (HY-131328). Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM.
-
Avitinib maleate dihydrate
0 ImagesCat. No.: HY-168427CAS No.: 1822357-78-7Synonyms: Abivertinib maleate dihydrate; AC0010 maleate dihydrateAvitinib (Abivertinib) maleate dihydrate is a third-generation, irreversible and orally active selective EGFR inhibitor, with IC50 values of 0.18 nM, 0.18 nM, 7.68 nM and against EGFR L858R, EGFR T790M and wild-type EGFR. Avitinib maleate dihydrate is also a BTK inhibitor that induces apoptosis and inhibits phosphorylation of BTK in mantle cell lymphoma. Avitinib maleate dihydrate shows anticancer effects.
-
(R)-Acalabrutinib
0 ImagesCat. No.: HY-W062695CAS No.: 1952316-43-6Synonyms: (R)-ACP-196(R)-Acalabrutinib ((R)-ACP-196) is the enantiomer of Acalabrutinib (HY-17600). (R)-Acalabrutinib is an inhibitor for Bruton’s tyrosine kinase (BTK).
-
CTA056
0 ImagesCat. No.: HY-110113CAS No.: 1265822-30-7
-
BTK-IN-37
0 ImagesCat. No.: HY-159589BTK-IN-37 (compound 8d) is a BTK inhibitor that can induce apoptosis in cancer cells. BTK-IN-37 targets BTK with Ki and IC50 of 5.07 nM and 3.6 nM, respectively. BTK-IN-37 can also selectively induce enrichment of genes involved in necroptosis and pyroptosis.
-
BTK-IN-19
0 ImagesCat. No.: HY-152212CAS No.: 1374240-01-3BTK-IN-19 (Compound 51) is a reversible BTK inhibitor with an IC50 of <0.001 μM.
-
BTK-IN-16
0 ImagesBTK-IN-16 is a dual inhibitor of BTK wild type and C481S mutant of Bruton’s tyrosine kinase (BTK) with IC50s of 5.1 and 4.1 μM. BTK-IN-16 can be used for the research of autoimmune diseases and chronic lymphocytic leukemia.
-
BTK-IN-3
0 ImagesCat. No.: HY-141689CAS No.: 1226872-27-0
